Contact Us

Dunbar dronabinol api

At Dunbar Pharmaceuticals, we produce EU GMP plant-derived Dronabinol API that adheres to the highest standards of safety, quality, and EU Good Manufacturing Practice (GMP) compliance.

Dunbar Pharma scientist holding a pharmaceutical-grade Dronabinol syringe for quality inspection under GMP standards, demonstrating precision in cannabinoid active ingredient manufacturing.

About Dronabinol

Dronabinol is a pharmaceutical-grade cannabinoid API used to treat conditions such as chemotherapy-induced nausea and vomiting, chronic pain, and severe appetite loss associated with conditions like HIV/AIDS and cancer.

Unlike traditional synthetic versions, Dunbar Pharma’s Dronabinol is a plant-derived, EU GMP-certified alternative.

Historically, Dronabinol has been synthetically produced since the 1980s as a pharmaceutical alternative to THC. Marketed under brands like Marinol, synthetic Dronabinol has been widely used but is often associated with slow absorption rates and high variability in patient response.

Dunbar Pharma is leading the shift to pharmaceutical grade plant-based Dronabinol, offering a product with a natural profile and sustainability advantages.

Request COAs, COCs, Certifications
Dunbar Pharma Product

Dronabinol Specifications

API Name: Dronabinol (Plant-Derived)

CAS Number: 1972-08-3

Molecular Formula: C₂₁H₃₀O₂

Purity: Achieving pharmaceutical-grade purities not found in the market.

Stability: Validated under ICH Q1A guidelines for long-term storage.

Why Choose Dunbar Dronabinol

Atrribute
Source
Certifications
Quality Control
Regulatory Engagement
Supply Chain
Sustainability
Production Capacity
Therapeutic Focus
Innovation
Education Commitment
Dunbar Pharmaceuticals Dronabinol
100% plant-derived cannabinoid APIs ensuring natural and sustainable products.
EU GMP-certified facility, guaranteeing compliance with stringent pharmaceutical standards.
In-house QC lab equipped with HPLC, GC-MS, and ICH-compliant stability chambers for rigorous testing.
Proactive collaboration with global authorities like HPRA and EMA since 2021.
Validated, export-ready logistics with full traceability and compliance in key markets.
Eco-conscious production utilizing minimal solvents and real-time environmental monitoring.
Scalable operations capable of producing over 220,000 units annually to meet global demand.
APIs indicated for conditions like chemotherapy-induced nausea, AIDS-related cachexia, and MS-related pain.
First-of-its-kind manufacturing platform for Dronabinol derived entirely from cannabis biomass.
Active involvement in scientific education and webinars with licensed partners in key markets.

Key Patient Groups & Therapeutic Benefits

Cancer Patients

Chemotherapy often induces severe nausea and vomiting that can make treatment unbearable. Dronabinol binds to CB1 receptors in the brainstem, suppressing nausea signals and allowing patients to eat, retain nutrients, and regain strength during treatment.

HIV/AIDS Patients

Up to 50% of AIDS patients suffer from cachexia (wasting syndrome), causing drastic weight loss. Dronabinol stimulates appetite, improves caloric intake, and helps maintain body weight, supporting better long-term outcomes.

Chronic Pain Patients
(Neuropathic & Multiple Sclerosis-Related)

Modulates pain signals in the spinal cord and brain, providing relief for conditions like neuropathy, multiple sclerosis, and fibromyalgia. Enhances mobility and daily function, reducing dependence on opioids.

Neurological Disorder Patients
(ALS, Parkinson’s, Epilepsy)

Studies suggest cannabinoids reduce muscle spasticity and tremors, improving quality of life for patients with conditions like ALS and Parkinson’s Disease. May aid in the management of treatment-resistant epilepsy.

Impact of Dronabinol

By producing 100% plant-derived Dronabinol APIs, Dunbar Pharmaceuticals enhances treatment options for patients suffering from chemotherapy-induced nausea, AIDS-related cachexia, and multiple sclerosis-related pain.